Autologous T lymphocytes engineered to express a chimeric antigen receptor that binds CD30 (TNFRSF8) on Hodgkin/Reed–Sternberg cells, enabling TCR-independent recognition and activation through CD3ζ and co-stimulatory domains, resulting in T-cell expansion, cytokine release, and perforin/granzyme-mediated lysis of CD30-positive tumor cells.